Drug Delivery
XR & Modified-Release Matrices
Hydrophilic polymer gel systems delivering constant 24-hour therapeutic plasma levels without fluctuations.
Ph. Eur. StandardR&D Validated
PARLA R&D SCIENTIFIC CENTER
Science & Pharmaceutical Innovations
Pioneering next-generation drug delivery, bioavailability enhancement, and rigorous bioequivalence research adhering to European Pharmacopoeia standards.
45+
Formulation Patents
100%
European Raw Materials
ISO 5
Cleanroom Class
350%
Bioavailability Gain
RESEARCH PILLARS
Parla Technological Platforms
Laboratory solutions maximizing clinical efficacy and patient compliance.
Nanotechnology
Nanocrystallization & Bioavailability
Sub-micron homogenization reducing particle sizes to 200-400 nm, increasing dissolution speed and absorption by 350%.
Ph. Eur. StandardR&D Validated
Cleanroom ISO
Green Chemistry & Eco-Pharma
Elimination of hazardous solvents via aqueous coating and zero-emission closed cleanroom environments.
Ph. Eur. StandardR&D Validated
Pharmacokinetics
Bioequivalence & LC-MS/MS Analytics
Ultra-sensitive mass spectrometry validating 100% pharmacokinetic equivalence to global reference originators.
Ph. Eur. StandardR&D Validated
SCIENTIFIC PUBLICATIONS
Clinical & Pharmacological Papers
Formulyasiya ElmiDOI: 10.1016/j.jconrel.parla.2026.014
Modified-Release XR Matrix Technology: Maintaining Stable Plasma Therapeutic Windows
Gradual dissolution within hydrophilic polymer matrices optimizing bioavailability and reducing GI side effects by 70%.
Read Paper
Extended Release (XR) dosage forms substantially improve patient compliance in the treatment of chronic conditions.
The hypromellose (HPMC) based hydrophilic gel matrix applied by the Parla R&D team swells immediately after intake, ensuring an even, hour-by-hour diffusion of the active molecules.
Clinical trials have shown that the XR formulation prevents sharp peaks in plasma concentration compared to conventional tablets and provides full control with a single daily dose.
NanotexnologiyaDOI: 10.1002/parla.nano.2026.088
Nanocrystallization & Bioavailability Enhancement of Poorly Soluble APIs
High-pressure homogenization reducing particle sizes to sub-micron scales to dramatically boost dissolution velocity.
Read Paper
More than 60% of newly synthesized molecules in modern pharmacology are poorly water-soluble, limiting their therapeutic effectiveness.
The "Top-Down Wet Milling" technology applied in Parla laboratories reduces active ingredient particles to a 200-400 nanometer range.
As a result, the specific surface area multiplies, dissolution accelerates according to the Noyes-Whitney equation, and absorption by the body increases by 350%.
Ekoloji ƏczaçılıqDOI: 10.1021/acs.parla.green.2026.002
Green Chemistry in Pharma & Eco-Compliant Cleanroom (ISO 14644) Standards
Replacing toxic volatile solvents with advanced aqueous film coating and closed-loop HEPA filtration cycles.
Read Paper
Parla Pharmaceuticals has switched to 100% water-based film coating systems in manufacturing to minimize environmental impact.
Our production blocks are fitted with differential air-pressure control and H14 HEPA filters performing 30-40 air changes per hour.
This eco-architecture guarantees both waste-free production and complete chemical cleanliness for operators and end consumers alike.
Klinik FarmakologiyaDOI: 10.1007/parla.clinpharm.2026.115
Bioequivalence Studies: Pharmacokinetic Concordance between Originators & Parla Formulations
Rigorous in-vivo pharmacokinetic crossover bioequivalence studies matching strict 80.00-125.00% confidence bounds.
Read Paper
Every medicine in the Parla portfolio holds a clinically proven bioequivalence certificate.
The rate and extent of drug absorption in blood plasma is determined with the most precise LC-MS/MS (Liquid Chromatography - Tandem Mass Spectrometry) instruments.
The results confirm that Parla formulations hold the same therapeutic strength and safety profile as the original brands.